Begüm EVRANOS AKSÖZ, Fatma Kaynak KAYNAK ONURDAĞ, Erkan AKSÖZ, Selda ÖZGEN

BAZI 4,5-DİHİDRO-1H-PİRAZOL VE ŞALKON TÜREVLERİNİN ANTİMİKROBİYAL VE ANTİTÜBERKÜLER ETKİLERİ ÜZERİNE ARAŞTIRMALAR

Amaç: Bu çalışmada öncelikle şalkonlar ve bu şalkon türevlerinin hidrazitler ile reaksiyonu sonucu halka kapanması ile oluşan 4,5-dihidro-1H-pirazol yapısındaki bileşikler sentez edilmiş ve sentezlenen tüm bileşiklerin antimikrobiyal ve antitüberküler etkileri araştırılmıştır.

INVESTIGATIONS ON ANTIMICROBIAL AND ANTITUBERCULAR ACTIVITY OF SOME 4,5-DIHYDRO-1H-PYRAZOLE AND CHALCONE DERIVATIVES

Objective: In this study, first of all, chalcones and the compounds in the structure of 4,5-dihydro-1H-pyrazole, which are formed by ring closure as a result of the reaction of the chalcones with hydrazides were synthesized and the antimicrobial and antitubercular effects of all synthesized compounds were investigated.

Keywords:

Antimicrobial activity, antitubercular activity, chalcone, 4.5-dihydro-1H-pyrazole,

PDF

___

KAYNAKLAR 1. Tsega, A., Mekonnen, F. (2019). Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia. BMC Pregnancy and Childbirth, 19, 527-534.
2. Vanani, A.R., Mahdavinia, M., Kalantari, H., Khoshnood, S., Shirani, M. (2019). Antifungal effect of the effect of Securigera securidaca L. vaginal gel on Candida species. Current Medical Mycology, 5(3), 31-35.
3. Oyewole, O.A., Okoliegbe, I.N., Alkhalil, S., Isah, P. (2013). Prevalence of vaginal candidiasis among pregnant women attending Federal University of Technology, Minna, Nigeria, Bosso Clinic. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 4(1), 113-120.
4. Samaranayake, Y.H., Samaranayake, L.P. (1994). Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. Journal of Medical Microbiology, 41, 295-310.
5. Nobile, C.J., Johnson, A.D. (2015). Candida albicans biofilms and human disease. Annual Review of Microbiology, 69, 71-92.
6. Kumar, K.A., Jayaroopa, P. (2013). Pyrazoles: synthetic strategies and their pharmaceutical applications-an overview. International Journal of PharmTech Research, 5(4), 1473-1486.
7. Naim, M.J., Alam, O., Nawaz, F., Alam, J., Alam, P. (2016). Current status of pyrazole and its biological activities. Journal of Pharmacy and BioAllied Sciences, 8(1), 2-17.
8. Kumar, S., Bawa, S., Drabu, S., Kumar, R., Gupta, H. (2009). Biological activities of pyrazoline derivatives -a recent development. Recent Patents on Anti-Infective Drug Discovery, 4(3), 154-163.
9. Karrouchi, K., Radi, S., Ramli, Y., Taoufik, J., Mabkhot, Y.N., Al-aizari, F.A., Ansar, M. (2018). Synthesis and pharmacological activities of pyrazole derivatives: a review. Molecules, 23, 134-218.
10. Evranos-Aksoz, B., Ucar, G., Tas, S.T., Aksoz, E., Yelekci, K., Erikci, A., Sara, Y., Iskit, A.B. (2017). New human monoamine oxidase A inhibitors with potential antidepressant activity: design, synthesis, biological screening and evaluation of pharmacological activity. Combinatorial Chemistry & High Throughput Screening, 20(6), 461-473.
11. Gomes, M.N., Muratov, E.N., Pereira, M., Peixoto, J.C., Rosseto, L.P., Cravo, P.V.L., Andrade, C. H., Neves, B. J. (2017). Chalcone derivatives: promising starting points for drug design. Molecules, 22(8), 1210.
12. Evranos Aksöz, B., Ertan, R. (2011). Chemical and structural properties of chalcones I. FABAD Journal of Pharmaceutical Sciences, 36, 223-242. 13. Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., Miao, Z. (2017). Chalcone: a privileged structure in medicinal chemistry. Chemical Reviews, 117(12), 7762-7810. 14. Sahu, N.K., Balbhadra, S.S., Choudhary, J., Kohli, D.V. (2012). Exploring pharmacological significance of chalcone scaffold: a review. Current Medicinal Chemistry, 19, 209-225.
15. Lin, Y.M., Zhou, Y., Flavın, M.T., Zhou, L.M., Nıe, W., Chen, F.C. (2002). Chalcones and flavonoids as anti-tuberculosis agents. Bioorganic and Medicinal Chemistry, 10, 2795-2802.
16. Jayasinghe, L., Balasooriya, B.A., Padmini, W.C., Hara, N., Fujimoto, Y. (2004). Geranyl chalcone derivatives with antifungal and radical scavenging properties from the leaves of Artocarpus nobilis. Phytochemistry, 65, 1287-1290.
17. Svetaz, L., Tapia, A., López, S.N., Furlán, R.L., Petenatti, E., Pioli, R., Schmeda-Hirschmann, G., Zacchino, S.A. (2004). Antifungal chalcones and new caffeic acid esters from Zuccagnia punctata acting against soybean infecting fungi. Journal of Agricultural Food Chemistry, 52, 3297-3330.
18. Özdemir, A., Turan-Zitouni, G., Kaplancıklı, Z.A., Revial, G., Demirci, F., İşcan, G. (2010). Preparation of some pyrazoline derivatives and evaluation of their antifungal activities. Journal of Enzyme Inhibition and Medicinal Chemistry, 25(4), 565-571.
19. Jimenez, C.M., Sampietro, D.A., Sgariglia, M.A., Soberón, J.R., Vattuone, M.A. (2014). Isolation, identification and usefulness of antifungal compounds from Zuccagnia punctata for control of toxigenic ear rot pathogens. Natural Products Communications, 9, 1461-1464.
20. Koudokpon, H., Armstrong, N., Dougnon, T.V., Fah, L., Hounsa, E., Bankolé, H.S., Loko, F., Chabrière, E., Rolain, J.M. (2018). Antibacterial activity of chalcone and dihydrochalcone compounds from Uvaria chamae roots against multidrug-resistant bacteria. BioMed Research International, 2018, 1453173.
21. Xu, M., Wu, P., Shen, F., Ji, J., Rakesh, K.P. Chalcone derivatives and their antibacterial activities: Current development. (2019). Bioorganic Chemistry, 91, 103133.
22. Ni, L., Meng, C.Q., Sikorski, J.A. (2004). Recent advances in therapeutic chalcones. Expert Opinion on Therapeutic Patents, 14(12), 1669-1691. 23. Evranos-Aksoz, B., Baysal, I., Yabanoglu-Ciftci, S., Djikic, T., Yelekci, K., Ucar, G., Ertan, R. (2015). Synthesis and screening of human Monoamine oxidase-A inhibitor effect of new 2-pyrazoline and hydrazone derivatives. Archive Der Pharmazie, 348, 743-756.
24. Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). (2006a). Performance standards for antimicrobial susceptibility testing 6th ınformational supplement. CLSI M100-S16, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne, Pennsylvania, USA.
25. Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). (2006b). Reference method for broth dilution antifungal susceptibility testing of yeast approved standard, M27-A, clinical and laboratory standards ınstitute, 940 West Valley Road, Wayne, Pennsylvania, USA.
26. Franzblau, S.G., Witzig, R.S., McLaughlin, J.C., Torres, P., Madico, G., Hernandez, A., Degnan, M.T., Cook, M.B., Quenzer, V.K., Ferguson, R.M., Gilman, R.H. (1998). Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamar blue assay. Journal of Clinical Microbiology, 36, 362-366.
27. Lin, Y.M., Zhou, Y., Flavin, M.T., Zhou, L.M., Nie, W., Chen, F.C. (2002). Chalcones and flavonoids as anti-tuberculosis agents. Bioorganic and Medicinal Chemistry, 10, 2795-2802.